A recent study has also already shown that the combination of a BET bromodomain inhibitor (which effectively downregulates MYC levels) with a specific BCL‐2 antagonist (ABT‐199) has synergistic antitumor activity in a xenograft mouse model of diffuse large B‐cell lymphoma (DLBCL) [33]. Here, BCL2 is linked to diffuse large B-cell lymphoma.